TrialInvestigational new drugs2005

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Mary J Mackenzie et al.PubMed ↗Publisher ↗

No numbers read from the abstract.